A Two-Part, Randomised, Open-Label, Evaluator-Blinded, Multiple-Dose, Phase I Pilot Study With OXP001 Ibuprofen 400 mg Tablets and Brufen® 400 mg Tablets to Assess the Comparative Bioavailability (Part 1) and Effects on Gastroduodenal Irritation (Part 2) in Healthy Human Subjects

Trial Profile

A Two-Part, Randomised, Open-Label, Evaluator-Blinded, Multiple-Dose, Phase I Pilot Study With OXP001 Ibuprofen 400 mg Tablets and Brufen® 400 mg Tablets to Assess the Comparative Bioavailability (Part 1) and Effects on Gastroduodenal Irritation (Part 2) in Healthy Human Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs Ibuprofen (Primary)
  • Indications Musculoskeletal pain
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors Oxford Pharmascience
  • Most Recent Events

    • 05 Nov 2015 Results published in an Oxford Pharmascience media release.
    • 27 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Aug 2015 According to an Oxford Pharmascience media release, the company has commenced dosing in the second phase of the study, in which the severity of upper GI damage will be assessed via endoscopic assessment following treatment with 2.4 g/day of ibuprofen dosed as either OXP001(2) or Brufen for 7 days. Headline results of the second phase are expected in Q4 2015, along with complete PK data and further taste masking assessments.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top